Clinical Trial Packaging: Kit Design, Blinding, and Regulatory Requirements

Clinical trial packaging is the process of putting investigational product into the containers and cartons a subject or site actually handles — and, in a controlled trial, doing so in a way that preserves the blind, matches a specific randomization assignment, and satisfies the labeling law of every country the kit will be used in. It is a narrower discipline than pharmaceutical packaging generally: a commercial drug’s label is fixed and public; a clinical trial kit’s label is often deliberately anonymized, printed in multiple languages on peel-off panels, and tied to a kit number that only the trial’s Interactive Response Technology (IRT/RTSM) system can map back to a treatment arm.

What “Clinical Trial Packaging” Covers

In practice, the term spans three related activities that are usually planned together rather than sequentially:

• Kit design — deciding what a “kit” (the packaged, labeled unit dispensed to one subject at one visit) physically contains: how many primary containers, what dosage strengths, whether comparator or placebo is co-packaged (double-dummy designs), and how the kit maps to the RTSM system’s numbering scheme.
• Primary and secondary packaging — the physical containers and cartons themselves, built to protect product stability (including cold-chain requirements where applicable) while carrying the printed, often multi-panel labeling regulators require.
• Labeling and re-labeling — producing the required label content for each jurisdiction the trial runs in, and managing over-labeling when an expiry date is extended or a kit is re-allocated to a different country’s stock.

Primary vs. Secondary Packaging

Primary packaging is whatever is in direct contact with the drug product — a blister strip, vial, ampoule, or bottle. It has to be chemically inert to the formulation, appropriate to the product’s stability profile, and, for biologics or temperature-sensitive compounds, compatible with the trial’s cold-chain handling.

Secondary packaging is the carton, wallet, or box that holds the primary containers together as a dispensable kit. This is where most of the trial-specific printed content lives: protocol and kit number, visit schedule, storage conditions, the required regulatory caution statement, and (in blinded trials) a design that gives no visual or tactile cue to which arm the kit belongs to. Secondary packaging is also typically where tamper-evidence and the emergency unblinding reference (a sealed panel or a pointer to the IRT/RTSM system) sit.

How Blinding Requirements Drive Packaging Design

In a blinded trial (see Blinding and Masking in Clinical Trials and the Open-Label vs. Double-Blind Trial Design comparison), packaging is one of the main places the blind can leak if it isn’t planned deliberately. Common design responses include:

• Identical-appearing kits across arms — matched size, weight, color, and printed layout, down to the shrink-wrap, so a site pharmacist or subject cannot infer assignment from the package alone.
• Over-encapsulation or double-dummy packaging, when the comparator’s own commercial packaging can’t be disguised any other way — each subject receives both an active-formulation kit and a matching placebo of the comparator’s presentation.
• Kit numbers instead of treatment names on every label, with the treatment mapping held only in the RTSM/IRT randomization system and released to the site only through a documented emergency-unblinding procedure.

Packaging and randomization design are worked out together, not packaging first and randomization after — a kit that visually distinguishes arms defeats the blind regardless of how rigorous the statistical randomization scheme is.

Randomization Schemes and Kit Design (RTSM-Driven Packaging)

How subjects are randomized (see Randomization Methods in Clinical Trials) has direct, practical consequences for how kits are built and distributed:

• Fixed randomization (simple, block, or stratified) allows kits to be pre-manufactured and pre-allocated to sites in bulk ahead of enrollment, since the treatment sequence is set in advance.
• Dynamic or adaptive randomization (minimization, response-adaptive designs) generally requires the RTSM system to assign a specific kit number to a specific subject in real time at the point of dispensing, which pushes trials toward “just-in-time” kit release from a depot rather than large pre-positioned site stock.

Either way, the RTSM/IRT platform is the system of record that reconciles kit inventory against randomization assignment, drives automatic resupply triggers as site stock is consumed, and enforces expiry-date logic so a site cannot dispense an expired kit. Packaging and supply planners size kit buffers to avoid stockouts (which can delay dosing visits) without over-producing kits that expire unused — a balance that becomes harder the more arms, dose levels, or stratification factors a design has. For how randomization interacts with the rest of trial design, see Designing a Clinical Trial: Endpoints, Sample Size, Randomization, SAP.

Regulatory Labeling Requirements

Clinical trial labeling is governed separately from, and generally more strictly than, commercial drug labeling, because the product is unapproved and the recipient may not know which treatment they are receiving:

• United States — FDA’s investigational new drug labeling regulation (21 CFR 312.6) requires that immediate-container labels bear the statement “Caution: New Drug—Limited by Federal Law to Investigational Use,” restrict labeling to information needed for safe use, and prohibit representations that the product is safe or effective for the purposes under investigation.
• European Union — the EU Clinical Trials Regulation (EU) No 536/2014 sets out labeling requirements for investigational medicinal products and auxiliary medicinal products in its Annex VI, specifying the minimum information an outer and immediate label must carry and when a reduced label (for products already authorized and unmodified) is permitted. Manufacture of investigational medicinal products for the EU market is separately governed by GMP requirements for investigational products.
• ICH GCP — ICH E6(R2) and the newer ICH E6(R3) place the obligation on the sponsor to ensure the Investigational Medicinal Product (IMP) is packaged and labeled to protect the blind (where applicable), maintain traceability, and provide instructions necessary for its proper use and storage; the product’s identity, dosage, and specifications are documented in the Investigational Medicinal Product Dossier (IMPD) submitted alongside the trial application, and, for a US IND-track product, in the Investigational New Drug (IND) application.

Multi-region trials typically solve the “one kit, many countries’ label law” problem with booklet or multi-panel labels — a base carton printed with peel-off or fold-out panels in each required language and format, rather than manufacturing a fully separate kit per country. This keeps a single manufacturing and blinding run usable across all participating sites.

Packaging’s Place in the Clinical Trial Supply Chain

Packaging and labeling decisions are made early in supply planning because they constrain almost everything downstream: how much can be pre-positioned at a depot, how resupply is triggered, how cold-chain logistics are configured, and how much lead time re-labeling or a shelf-life extension needs before existing kits expire. For the broader supply chain this fits into — forecasting, depot and site inventory, distribution, and drug accountability — see the Clinical Trial Supply Management guide, which this page extends with a deeper look specifically at kit design, packaging structure, and labeling.

Common Packaging-Driven Challenges

• Stockout vs. waste balance — kit buffers sized too small delay dosing visits when resupply lags; buffers sized too large risk expiring, unused kits, especially in adaptive designs with unpredictable arm-level enrollment.
• Over-labeling for shelf-life extensions — when stability data supports a longer expiry than originally labeled, sponsors must re-label existing kits (typically with an added or replacement expiry panel) under documented, auditable procedures rather than simply reissuing new stock.
• Comparator packaging — sourcing and re-packaging a commercially marketed comparator into blinded, trial-specific kits (often via over-encapsulation) adds a manufacturing and stability-testing step the sponsor’s own investigational product doesn’t require.
• Combination products and devices — trials involving a drug-device combination or companion diagnostic add packaging components (applicators, diluents, device manuals) that must be co-kitted and labeled without breaking the blind or the device’s own regulatory requirements.

Frequently Asked Questions

What are the requirements for clinical trial packaging?

There is no single “packaging requirement” — requirements come from three sources that have to be satisfied together: the trial’s blinding design (packaging must not reveal treatment assignment), ICH GCP’s sponsor obligations for IMP handling and traceability, and the labeling law of each country where the kit will be used (21 CFR 312.6 in the US; Annex VI of the EU Clinical Trials Regulation in the EU, plus each other participating country’s equivalent).

What does “clinical trial packaging and labeling” actually include?

It covers the primary container (what touches the product), the secondary carton or wallet (what carries the printed trial-specific information and blinding design), and the label content itself — protocol/kit identifiers, storage conditions, the investigational-use caution statement, and, for multi-region trials, multilingual labeling panels.

Is there a distinct market for clinical trial packaging?

Yes — clinical trial (or “clinical”) packaging is a recognized specialization within the broader pharmaceutical contract packaging and clinical supply industry, served by dedicated clinical packaging organizations (CPOs) and CDMOs alongside in-house sponsor packaging operations, distinct from commercial pharmaceutical packaging because of the blinding, kit-numbering, and multi-country labeling requirements described above.